logo

GYRE

Gyre Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

GYRE fundamentals

Gyre Therapeutics (GYRE) released its earnings on Nov 7, 2025: revenue was 30.56M (YoY +19.90%), missed estimates; EPS was 0.03 (YoY +200.00%), beat estimates.
Revenue / YoY
30.56M
+19.90%
EPS / YoY
0.03
+200.00%
Report date
Nov 7, 2025
EPS
Revenue

Revenue & Expenses

GYRE has released its 2025 Q3 earnings report, with revenue of 30.56M, reflecting a YoY change of 19.92%, and net profit of 5.94M, showing a YoY change of 107.84%. The Sankey diagram below clearly presents GYRE's revenue sources and cost distribution.

Key Indicators

Gyre Therapeutics (GYRE) key financial stats and ratios, covering profitability, financial health, and leverage.
Gyre Therapeutics (GYRE)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Gyre Therapeutics (GYRE)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Gyre Therapeutics (GYRE)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Gyre Therapeutics (GYRE) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Gyre Therapeutics (GYRE) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield